{
    "nctId": "NCT06104371",
    "briefTitle": "Lymph Node Identification Using Magtrace and Magseed Before Chemotherapy",
    "officialTitle": "Axillary Lymph Node Identification Before Neoadjuvant Chemotherapy Using Magtrace, (Superparamagnetic Iron Oxide Nanoparticles, SPIO) and Magseed, in Clinically Node Negative and Node Positive Patients. SentiNeo 2.0",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 459,
    "primaryOutcomeMeasure": "Sentinel lymph node detection rate",
    "eligibilityCriteria": "Inclusion criteria:\n\n* Patients 18 years of age or older.\n* Patients with breast cancer planned to undergo NACT with\n\n  * planned sentinel lymph node dissection (SLND), or\n  * targeted axillary lymph node dissection (TAD), in conjunction with the\n* breast surgery after NACT.\n\nExclusion Criteria:\n\n* Intolerance / hypersensitivity to iron or dextran compounds or SPIO.\n* Patients who are required to undergo MRI to evaluate tumour response.\n* Pregnancy or breast feedin.g\n* Patients with an iron overload disease.\n* Patient deprived of liberty or under guardianship.\n* Inability to understand given information and give informed consent or undergo study procedure",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}